Anesthetic drugs & techniques

Target-controlled Infusion of Remimazolam in Healthy Volunteers Shows Some Acute Tolerance

AnesthesiologyPublished Pharmacokinetic-pharmacodynamic modelling study

Authors' conclusion

In this study, it was shown that remimazolam-induced sedation is prone to tolerance development, which is potentially mediated by the CNS7054 concentration.

Study context

Population
Healthy volunteers receiving remimazolam alone by target-controlled infusion (TCI)first period data
Participants
24 volunteers
Comparison
PK-PD models without vs with tolerance
Outcome
Relationship between remimazolam concentration, MOAAS score and BIS
Methodological detailsanalysis of a crossover dose-ranging clinical trial, three-period crossover, age and sex stratification, step-up and step-down TCI protocol, nonlinear mixed-effects modelling
  • Analysis of a crossover dose-ranging clinical trial
  • Three-period crossover
  • Age and sex stratification
  • Step-up and step-down TCI protocol
  • Nonlinear mixed-effects modelling

Main finding

As reported in the abstract

Remimazolam–BIS–MOAAS relationship
Tolerance significantly improved overall model fit for BIS and Modified Observer's Assessment of Alertness and Sedation (MOAAS) models
P < 0.01

Further findings

OutcomeWithout toleranceWith tolerance
Predicted BIS after 30 min repeated bolus dosing (procedural sedation label regimen)54 (95% prediction interval 44–67)58 (95% prediction interval 48–70)
Predicted probability of MOAAS 2/3 after 30 min repeated bolus dosing2% (95% prediction interval 0–32%)8% (95% prediction interval 0–36%)
Predicted BIS after 60 min continuous infusion (GA label regimen)40 (95% prediction interval 33–50)50 (95% prediction interval 41–60)
Predicted probability of MOAAS 0 after 60 min continuous infusion87% (95% prediction interval 18–100%)59% (95% prediction interval 6–99%)

Original publication

Target-controlled Infusion of Remimazolam in Healthy Volunteers Shows Some Acute Tolerance. Anesthesiology. Published 27 October 2023. doi:10.1097/aln.0000000000004811

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.